Sanjeev Jain, MD
Hematology & Oncology · East Patchogue, NYNPI 1851497341
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $969,550 of the $971,487 with a category attached, or 99.8%. Pfizer accounts for 81.9% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $440,074, more than ten times the $43,313 reported in 2019. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $10,446 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$795K
- Incyte Corporation$92K
- Merck$82K
- Innate Pharma, Inc$1K
- Novocure Inc.$149
- Johnson & Johnson$128
- plus $345 from 7 others
Across 45 payments — averaging $4742.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acerta Pharma LLC$120K
- Astrazeneca UK Limited$56K
- AbbVie$14K
- Morphosys AG$8K
- EMD Serono, Inc.$6K
- Beigene (suzhou) Co., Ltd.$5K
- plus $4K from 4 others
What the payments were for
- Consulting fees$969,550100%
- Speaking & faculty fees$1,2000%
- Food & beverage$6260%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 40 | $795,200 |
| Incyte Corporation | 17 | $92,350 |
| Merck | 20 | $82,116 |
| Innate Pharma, Inc | 1 | $1,200 |
| Novocure Inc. | 1 | $149 |
| Johnson & Johnson | 2 | $128 |
| Lilly USA, LLC | 1 | $120 |
| Gilead(2 entities) | 4 | $73 |
| Genentech USA, Inc. | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| CTI Biopharma Corp. | 1 | $23 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELREXFIO$795,200
- KEYTRUDA$82,041
- LUMOXITI$1,200
- OPTUNE LUA (NOVOTTF-200T)$149
- JAYPIRCA$120
How this compares
$971,487 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ReblozylLuspatercept-Aamt | 32 | $682,789 |
| AranespDarbepoetin Alfa In Polysorbat | 194 | $661,615 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 71 | $521,093 |
| RevlimidLenalidomide | 26 | $337,246 |
| KeytrudaPembrolizumab | 25 | $279,152 |
| LynparzaOlaparib | 15 | $245,932 |
| CalquenceAcalabrutinib Maleate | 17 | $238,285 |
| MvasiBevacizumab-Awwb | 20 | $191,073 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 18 | $189,264 |
| XtandiEnzalutamide | 13 | $183,243 |
| XgevaDenosumab | 38 | $115,751 |
| TreandaBendamustine Hcl | 14 | $104,015 |
| NeulastaPegfilgrastim | 13 | $94,671 |
| AkynzeoFosnetupitant/Palonosetron | 72 | $78,925 |
| Neulasta OnproPegfilgrastim | 13 | $77,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Eliquis | $795,200 | $537,65698 claims |
| MerckKeytruda | $82,116 | $279,15225 claims |
| Johnson & JohnsonXarelto | $128 | $38,02248 claims |
| Lilly USA, LLCOlanzapine | $120 | $25313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in East Patchogue
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.